Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival
Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Richard M. Stone(Dana-Farber Cancer Institute), Scott Hall, James K. Mangan(UC San Diego Health System), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kimberley Doucette(Georgetown University), Carolin S. Escherich(St. Jude Children's Research Hospital), Shira Dinner(Dana-Farber Cancer Institute), Rebecca Teske(Alliance Data (United States)), Zhenhua Li(St. Jude Children's Research Hospital), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Jun Yin(Mayo Clinic), Caner Saygin(University of Chicago), Jun Yang(Second Affiliated Hospital of Guangzhou Medical University), Ken Byrd(University of Kansas), Ali W. Bseiso(University Hospitals of Cleveland), Mark Litzow(Toyota Motor Corporation (Switzerland)), Wendy Stock(University of Chicago), Katarzyna Jamieson(University of North Carolina at Chapel Hill), Oudom Kour(Alliance Data (United States))
Cited by 2
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825